Elanco: brands it owns and its ownership tree
Elanco (NYSE: ELAN) is a publicly listed company headquartered in Indianapolis, United States that owns 15 consumer brands.[1][2]
Elanco Animal Health is an Indianapolis animal health company with pet health and farm animal businesses. Its 10-K says it has a heritage dating to 1954 as a business unit of Eli Lilly and Company, was incorporated independently in September 2018 and separated in March 2019, and in August 2020 acquired Bayer Animal Health, which it calls the largest acquisition in industry history. It sells flea and tick, dermatology and pain products for pets and feed additives, vaccines and antibiotics for livestock.
-
brands owned
-
1
categories
-
0
acquisitions recorded
-
0
divestitures recorded
Company facts
- Legal name
- Elanco Animal Health Incorporated
- Type
- publicly listed company · see all publicly listed company owners
- Headquarters
- 🇺🇸 Indianapolis, United States
- Founded
- 1954
- Tickers
- NYSE: ELAN
- Revenue
- $4.71 billion (2025)[2]
- SEC CIK
- 0001739104
- Website
- www.elanco.com
- Last verified
- · 4 sources
What Elanco's annual report says about its business
Read from Elanco's latest annual filing[1]. Each line gives the sentence the filing uses, copied word for word.
Acquisitions and disposals named in the filing
- Acquired: Bayer Animal Health (August 2020).
In August 2020 we acquired Bayer Animal Health, marking the largest acquisition in industry history.
- Sold or exited: Manukau, New Zealand, site (2025).
Conversely, we may determine it appropriate to divest or close a manufacturing facility, such as the divestiture of our Manukau, New Zealand, site during 2025 or the planned closure of our Kansas City, Kansas, site in 2026.
Elanco in numbers
- Elanco owns 15 consumer brands tracked here across 1 top-level categories; the largest is pet & animal care with 15 brands.[1]
Elanco financial history
Headline figures from Elanco's annual reports filed with the US Securities and Exchange Commission, in USD as reported, fiscal years ending 2020–2025. Revenue moved from $3.27bn to $4.71bn, an average of 7.6% a year (calculated).
| Fiscal year ended | Revenue | Operating income | Operating margin | Net income | Total assets | Long-term debt | Filing |
|---|---|---|---|---|---|---|---|
| $4.71bn | — | — | $-232,000,000 | $13.4bn | — | 10-K | |
| $4.44bn | — | — | $338m | $12.6bn | $4.28bn | 10-K | |
| $4.42bn | — | — | $-1,231,000,000 | $14.4bn | $5.74bn | 10-K | |
| $4.41bn | — | — | $-78,000,000 | $15.5bn | $5.45bn | 10-K | |
| $4.76bn | — | — | $-483,000,000 | $16.5bn | $6.03bn | 10-K | |
| $3.27bn | — | — | $-574,000,000 | $17.7bn | $5.57bn | 10-K |
Source: SEC XBRL company facts. A dash means the company did not report that line in a form we could read. Figures for a year can be restated in a later filing; the latest filing's number is shown.
Everything Elanco owns
Controlling ownership as of . Brands grouped under the entity that owns them; large groups are collapsed.
Full-screen interactive tree → · Download as infographic
Brand portfolio by category
Recent changes to this record
Elanco SEC filings
The documents behind the figures on this page, as listed in the SEC's EDGAR index. Each links to the filing itself.
Annual reports
- Annual report, filed (10-K)
- Annual report, filed (10-K)
- Annual report, filed (10-K)
- Annual report, filed (10-K)
- Annual report, filed (10-K)
- Annual report, filed (10-K)
Proxy statements
- Proxy statement, filed (DEF 14A)
- Proxy statement, filed (DEF 14A)
- Proxy statement, filed (DEF 14A)
Recent current and quarterly reports
| Filed | Form | What it declares |
|---|---|---|
| 10-Q | Quarterly report | |
| 8-K | Results of operations and financial condition | |
| 8-K | Results of a shareholder vote | |
| 10-Q | Quarterly report | |
| 8-K | Results of operations and financial condition | |
| 8-K | Results of operations and financial condition | |
| 8-K | Regulation FD disclosure | |
| 8-K | Costs of exit or disposal activities; Regulation FD disclosure | |
| 10-Q | Quarterly report | |
| 8-K | Results of operations and financial condition | |
| 8-K | Entry into a material agreement; Creation of a direct financial obligation |
Frequently asked questions
What brands does Elanco own?
Elanco owns 15 consumer brands tracked here, including Advantage, Seresto, Atopica, Onsior, Galliprant and Interceptor Plus.
Is Elanco an American company?
Yes. Elanco is headquartered in Indianapolis, United States and was founded in 1954.
Who owns Elanco?
Elanco is a publicly listed company owned by its shareholders; it trades as ELAN on the NYSE.
Sources (4) & corrections
Last verified . Every ownership fact above is backed by one of these primary documents. Numbers in brackets in the text refer to this list.
- [1] Elanco Animal Health Incorporated Annual Report on Form 10-K filed 2026-02-24 — SEC EDGAR, SEC Form 10-K, published 24 February 2026; retrieved 2 October 2026.
- [2] Elanco Animal Health Incorporated: Form 10-K for the year ended 2025-12-31 (revenue) — SEC EDGAR, SEC Form 10-K, published 24 February 2026; retrieved 4 October 2026.
- [3] Elanco Animal Health Incorporated Form 8-K filed 2020-08-03: completion of the acquisition of Bayer Animal Health — SEC EDGAR, SEC Form 8-K, published 3 August 2020; retrieved 2 October 2026.
- [4] Elanco Finalizes Acquisition of Aratana Therapeutics — Elanco Animal Health Incorporated, Official press release, published 18 July 2019; retrieved 2 October 2026.
Report a correction Opens a pre-filled GitHub issue. See our corrections policy.